2/10
07:02 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/10
07:00 am
regn
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Low
Report
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
2/9
10:05 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.
2/8
02:04 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
2/6
12:36 pm
regn
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback [Yahoo! Finance]
Low
Report
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback [Yahoo! Finance]
2/5
11:55 pm
regn
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory [Yahoo! Finance]
2/2
01:32 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at JPMorgan Chase & Co. from $850.00 to $950.00. They now have an "overweight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at JPMorgan Chase & Co. from $850.00 to $950.00. They now have an "overweight" rating on the stock.
2/2
01:00 pm
regn
Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says [Yahoo! Finance]
Low
Report
Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says [Yahoo! Finance]
2/2
12:47 pm
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $865.00 price target on the stock, up previously from $750.00.
2/2
11:51 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $768.00 to $769.00. They now have an "equal weight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $768.00 to $769.00. They now have an "equal weight" rating on the stock.
2/2
10:47 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $745.00 to $800.00. They now have an "equal weight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Wells Fargo & Company from $745.00 to $800.00. They now have an "equal weight" rating on the stock.
2/2
10:47 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $740.00 to $800.00. They now have an "overweight" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $740.00 to $800.00. They now have an "overweight" rating on the stock.
2/2
10:01 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by analysts at Truist Financial Corporation from $820.00 to $818.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lowered by analysts at Truist Financial Corporation from $820.00 to $818.00. They now have a "buy" rating on the stock.
2/2
08:29 am
regn
Regeneron Pharmaceuticals raises dividend by 6.8% to $0.94 [Seeking Alpha]
Low
Report
Regeneron Pharmaceuticals raises dividend by 6.8% to $0.94 [Seeking Alpha]
2/2
07:13 am
regn
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases [Yahoo! Finance]
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases [Yahoo! Finance]
2/2
07:00 am
regn
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
2/1
02:29 pm
regn
Regeneron Pipeline Progress And Valuation Gap Put Future Growth In Focus [Yahoo! Finance]
Low
Report
Regeneron Pipeline Progress And Valuation Gap Put Future Growth In Focus [Yahoo! Finance]
1/31
07:03 pm
regn
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines [Yahoo! Finance]
1/31
04:58 pm
regn
Regeneron (REGN) Draws Higher Target From TD Cowen [Yahoo! Finance]
Low
Report
Regeneron (REGN) Draws Higher Target From TD Cowen [Yahoo! Finance]
1/31
03:52 pm
regn
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
Low
Report
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results [Yahoo! Finance]
1/30
07:12 pm
regn
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
Low
Report
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates [Yahoo! Finance]
1/30
04:20 pm
regn
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals Inc (REGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... [Yahoo! Finance]
1/30
03:21 pm
regn
Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth [Seeking Alpha]
Low
Report
Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth [Seeking Alpha]
1/30
08:05 am
regn
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 [Yahoo! Finance]
Low
Report
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025 [Yahoo! Finance]
1/30
06:30 am
regn
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Low
Report
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results